18.12.2015
- US biopharmaceutical group Amgen is buying back from GlaxoSmithKline (GSK) all of its remaining rights to the bone drugs Prolia (denosumab), Xgeva (denosumab) and Vectibix...
07.10.2015
- With biosimilars the pharmaceutical industry and health-care business move into a relatively young discipline with high sales potential. The follow-up drugs of biopharmaceuticals...
07.10.2015
- The pharmaceutical industry is entering a period of sustained growth. Prescription drug sales are set to advance at almost 5% a year until 2020, while worldwide prescription drug...
21.09.2015
- US biopharmaceutical group Amgen is to acquire Dezima Pharma, a privately held Dutch biotechnology company focused on developing treatments for dyslipidemia. The transaction is...
14.09.2015
- As a first step toward doubling its manufacturing and production capacity for biologics in the US, AstraZeneca has acquired a high-tech biologics bulk manufacturing facility in...
04.09.2015
- Canadian drugmaker Valeant has said it will work with AstraZeneca on a potential treatment for psoriasis, brodalumab, taking up the gauntlet from Amgen, which recently curtailed...
03.09.2015
- Swiss drugmaker Novartis has announced it will cooperate with US biopharmaceutical group Amgen to develop and sell neuroscience treatments for conditions such as Alzheimer's...
31.08.2015
- The US Food and Drug Administration has released a proposal for naming biosimilars – lower-cost biotech drugs – almost simultaneously with the market launch of the first such...
